IP Library Granted Patent US 12,473,557
Granted Patent B2
US 12,473,557 · App. 17/711,401 · Granted Nov 18, 2025

Engineered guanylate kinase variant enzymes

Inventors: Da Duan (Foster City, CA); Auric Anthony Sowell-Kantz (Mill Valley, CA); Aksiniya Lyubenova Petkova (Sunnyvale, CA); Oscar Alvizo (Fremont, CA)
Assignee: Codexis, Inc.
C12N15/52C12N9/12C12N15/63C12Y207/04008
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,473,557
App. No.
17/711,401
Granted
Nov 18, 2025
Kind
B2
Abstract

The present invention provides engineered guanylate kinase (GK) enzymes, polypeptides having GK activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing GK enzymes are also provided. The present invention further provides compositions comprising the GK enzymes and methods of using the engineered GK enzymes. The present invention finds particular use in the production of pharmaceutical compounds.

Claims (15)

1 . An engineered guanylate kinase comprising a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 4, wherein the polypeptide sequence of said engineered guanylate kinase comprises a substitution at position 144 and wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 4.

2 . The engineered guanylate kinase of claim 1 , wherein said polypeptide sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 4, and wherein the polypeptide sequence of said engineered guanylate kinase comprises further at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from the group consisting of 82/115/193/200, 42, 41, 60, 77, 83, 115, 116, 142, 150, 153, 157, and 176, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 4.

3 . The engineered guanylate kinase of claim 1 , wherein said polypeptide sequence of said engineered guanylate kinase has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 4, and wherein said polypeptide sequence of said engineered guanylate kinase further comprises at least one substitution or substitution set at one or more positions selected from the group consisting of 82/115/193/200, 82, 82/100, 82/100/115/116, 82/100/115/116/160/193, 82/100/116/160, 82/100/116/200, 82/100/160/200, 82/100/193, 82/100/200/203, 82/115/116, 82/115/116/193/200, 82/115/116/172, 82/115/160, 82/115/193, 82/116, 82/116/160, 82/116/193, 82/193, 82/160/172, 82/160/179, 82/160/193/200, 82/172, 82/193, 82/193/203, 82/200, 91, 100/172, 100/193, 115, 115/160, 115/193, 115/200, 193, 193/200, and 200, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 4.

4 . The engineered guanylate kinase of claim 1 , wherein said polypeptide sequence of said engineered guanylate kinase further has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 46, and wherein said polypeptide sequence of said engineered guanylate kinase further comprises at least one substitution or substitution set at one or more positions selected from the group consisting of 41, 41/42, 41/42/91, 41/42/91/134, 41/42/91/134/160, 41/42/91/160, 41/42/91/172, 41/42/134, 41/42/134/160, 41/42/134/150, 41/42/134/150/160, 41/42/134/160, 41/42/134/160/172, 41/42/160, 41/42/160/172, 41/42/172, 42, 42/91, 42/91/134, 42/91/134/172, 42/91/172, 42/134, 42/134/172, and 42/160, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 46.

5 . The engineered guanylate kinase of claim 1 , wherein said polypeptide sequence of said engineered guanylate kinase further has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 46, and wherein said polypeptide sequence of said engineered guanylate kinase further comprises at least one substitution or substitution set at one or more positions selected from the group consisting of 9/41/42, 9/41/42/60/115, 9/41/42/115/150/153, 9/41/42/115/153, 9/41/42/115/153/157, 9/41/42/115/157, 9/42/115/150/157/176, 9/60/150/153, 41/42, 41/42/60, 41/42/60/77/153/157, 41/42/60/115, 41/42/60/115/150, 41/42/60/115/150/153, 41/42/60/115/150/153/157, 41/42/60/115/150/153/176, 41/42/60/115/150/157, 41/42/60/115/153/176, 41/42/60/115/176, 41/42/60/150/153, 41/42/60/153, 41/42/60/153/157, 41/42/60/157, 41/42/77, 41/42/77/115, 41/42/77/115/153, 41/42/77/115/153/157, 41/42/77/115/157, 41/42/77/150, 41/42/77/153, 41/42/79/115/150/157, 41/42/83/150/153, 41/42/115, 41/42/115/150, 41/42/115/150/153, 41/42/115/150/153/157, 41/42/115/150/157/176, 41/42/115/153, 41/42/115/153/157, 41/42/115/157, 41/42/115/176, 41/42/150/153, 41/42/153, 41/42/153/157, 41/42/153/157/176, 41/42/157, 41/42/176, 41/60/77/115/150/157, 41/150, 41/150/157, 42, 42/60, 42/60/77/150/153, 42/60/115/150/153, 42/60/115/153, 42/60/150/153/157, 42/60/157, 42/60/176, 42/77/115/150/157, 42/115, 42/115/150/153, 42/150, 42/150/153, 42/150/153/157, 42/153, 42/153/157, 42/157, 60/150/153, 150/153, 150/153/176, 150/157, and 153/157, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 46.

6 . The engineered guanylate kinase of claim 1 , wherein said engineered guanylate kinase comprises the variant engineered guanylate kinase set forth in SEQ ID NO: 46.

7 . The engineered guanylate kinase of claim 1 , wherein said engineered guanylate kinase comprises a polypeptide sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence selected from the group consisting of SEQ ID NOs: 18, 22, 46, 48, 52, 54, 56, 62, 66, 70, 72, 74, 78, 80, 108, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 228, 230, 232, 234, 236, 238, 240, 242, 244, 246, 248, 250, 252, 254, 256, 258, 260, 262, 264, 266, 268, 270, 272, 274, 276, 278, 280, 282, 284, 286, 288, 290, 292, 294, 296, 298, 300, 302, 304, 306, 308, 310, 312, 314, 316, 318, 320, 322, 324, 326, 328, 330, 332, 334, 336, 338, 340, 342, 346, 348, 350, 352, 354, 356, 358, 360, 362, 364, 366, 368, 370, 372, 374, 376, 378, 380, 382, 384, 386, 388, 390, 392, 394, 396, 398, 400, 402, 404, 406, 408, 410, 412, 414, 416, 418, 420, 422, 424, 426,428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458, 460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 500, 502, 504, 506, 508, 510, 512, 514, 516, 518, 520, 522, 524, 526, 528, 530, 532, 534, 536, 538, 540, 542, 544, 546, 548, 550, and 552.

8 . The engineered guanylate kinase of claim 1 , wherein said engineered guanylate kinase comprises a polypeptide sequence set forth in any of SEQ ID NOs: 18, 22, 46, 48, 52, 54, 56, 62, 66, 70, 72, 74, 78, 80, 108, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 228, 230, 232, 234, 236, 238, 240, 242, 244, 246, 248, 250, 252, 254, 256, 258, 260, 262, 264, 266, 268, 270, 272, 274, 276, 278, 280, 282, 284, 286, 288, 290, 292, 294, 296, 298, 300, 302, 304, 306, 308, 310, 312, 314, 316, 318, 320, 322, 324, 326, 328, 330, 332, 334, 336, 338, 340, 342, 346, 348, 350, 352, 354, 356, 358, 360, 362, 364, 366, 368, 370, 372, 374, 376, 378, 380, 382, 384, 386, 388, 390, 392, 394, 396, 398, 400, 402, 404, 406, 408, 410, 412, 414, 416, 418, 420, 422, 424, 426,428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458, 460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 500, 502, 504, 506, 508, 510, 512, 514, 516, 518, 520, 522, 524, 526, 528, 530, 532, 534, 536, 538, 540, 542, 544, 546, 548, 550, and 552.

9 . The engineered guanylate kinase of claim 1 , wherein said engineered guanylate kinase exhibits increased activity on a substrate as compared to the activity of an enzyme having the polypeptide sequence set forth in SEQ ID NO:4, wherein said substrate comprises 3′F-3′-deoxyguanosine-5′-(1-thio)-monophosphate and/or Sp-2′F-ara-adenosine-5′-(1-thio)-triphosphate.

10 . The engineered guanylate kinase of claim 1 , wherein said engineered guanylate kinase exhibits increased production of Sp-3′F-3′-deoxyguanosine-5′-(1-thio)-diphosphate as compared to an enzyme having the polypeptide sequence set forth in SEQ ID NO:4.

11 . The engineered guanylate kinase of claim 1 , wherein said engineered guanylate kinase is purified.

12 . A composition comprising at least one engineered guanylate kinase of claim 1 .

13 . A method of producing an engineered guanylate kinase of claim 1 in a host cell, comprising culturing the host cell comprising at least one expression vector comprising a polynucleotide sequence encoding at least one engineered guanylate kinase of claim 1 , under suitable conditions, such that at least one engineered guanylate kinase is produced.

14 . The method of claim 13 , further comprising the step of purifying said at least one engineered guanylate kinase.

15 . The method of claim 13 , further comprising recovering the at least one engineered guanylate kinase from the host cell.

Assignments (2)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2022
From: DUAN, DA; SOWELL-KANTZ, AURIC ANTHONY; PETKOVA, AKSINIYA LYUBENOVA; ALVIZO, OSCAR
To: CODEXIS, INC.
Reel/Frame 060019/0477 →
Continuity (2)
Provisional Application 63170004 · Apr 2, 2021
Related Publication 20220325284A1 · Oct 13, 2022
References Cited (216)
US 5605793A · Stemmer · 1997 [cited by applicant]
US 5811238A · Stemmer et al. · 1998 [cited by applicant]
US 5830721A · Stemmer et al. · 1998 [cited by applicant]
US 5834252A · Stemmer et al. · 1998 [cited by applicant]
US 5837458A · Minshull et al. · 1998 [cited by applicant]
US 5928905A · Stemmer et al. · 1999 [cited by applicant]
US 6096548A · Stemmer · 2000 [cited by applicant]
US 6117679A · Stemmer · 2000 [cited by applicant]
US 6132970A · Stemmer · 2000 [cited by applicant]
US 6165793A · Stemmer · 2000 [cited by applicant]
US 6180406B1 · Stemmer · 2001 [cited by applicant]
US 6251674B1 · Tobin et al. · 2001 [cited by applicant]
US 6265201B1 · Wackett et al. · 2001 [cited by applicant]
US 6277638B1 · Stemmer · 2001 [cited by applicant]
US 6287861B1 · Stemmer et al. · 2001 [cited by applicant]
US 6287862B1 · delCardayre et al. · 2001 [cited by applicant]
US 6291242B1 · Stemmer · 2001 [cited by applicant]
US 6297053B1 · Stemmer · 2001 [cited by applicant]
US 6303344B1 · Patten et al. · 2001 [cited by applicant]
US 6309883B1 · Minshull et al. · 2001 [cited by applicant]
US 6319713B1 · Patten et al. · 2001 [cited by applicant]
US 6319714B1 · Crameri et al. · 2001 [cited by applicant]
US 6323030B1 · Stemmer · 2001 [cited by applicant]
US 6326204B1 · delCardayre et al. · 2001 [cited by applicant]
US 6335160B1 · Patten et al. · 2002 [cited by applicant]
US 6335198B1 · delCardayre et al. · 2002 [cited by applicant]
US 6337186B1 · Krebber · 2002 [cited by applicant]
US 6344356B1 · Stemmer · 2002 [cited by applicant]
US 6352859B1 · delCardayre et al. · 2002 [cited by applicant]
US 6355484B1 · Patten et al. · 2002 [cited by applicant]
US 6358740B1 · Patten et al. · 2002 [cited by applicant]
US 6358742B1 · Stemmer · 2002 [cited by applicant]
US 6365377B1 · Patten et al. · 2002 [cited by applicant]
US 6365408B1 · Stemmer · 2002 [cited by applicant]
US 6368861B1 · Crameri et al. · 2002 [cited by applicant]
US 6372497B1 · Stemmer · 2002 [cited by applicant]
US 6376246B1 · Crameri et al. · 2002 [cited by applicant]
US 6379964B1 · delCardayre et al. · 2002 [cited by applicant]
US 6387702B1 · Stemmer · 2002 [cited by applicant]
US 6391552B2 · Stemmer · 2002 [cited by applicant]
US 6391640B1 · Minshull et al. · 2002 [cited by applicant]
US 6395547B1 · Stemmer · 2002 [cited by applicant]
US 6406855B1 · Patten et al. · 2002 [cited by applicant]
US 6406910B1 · Patten et al. · 2002 [cited by applicant]
US 6413745B1 · Patten et al. · 2002 [cited by applicant]
US 6413774B1 · Stemmer · 2002 [cited by applicant]
US 6420175B1 · Stemmer · 2002 [cited by applicant]
US 6423542B1 · Crameri et al. · 2002 [cited by applicant]
US 6426224B1 · Crameri et al. · 2002 [cited by applicant]
US 6436675B1 · Welch et al. · 2002 [cited by applicant]
US 6444468B1 · Stemmer et al. · 2002 [cited by applicant]
US 6455253B1 · Patten et al. · 2002 [cited by applicant]
US 6479652B1 · Crameri et al. · 2002 [cited by applicant]
US 6482647B1 · Stemmer · 2002 [cited by applicant]
US 6483011B1 · Stemmer et al. · 2002 [cited by applicant]
US 6484105B2 · Zhang · 2002 [cited by applicant]
US 6489146B2 · Stemmer et al. · 2002 [cited by applicant]
US 6500617B1 · Stemmer et al. · 2002 [cited by applicant]
US 6500639B2 · Subramanian · 2002 [cited by applicant]
US 6506602B1 · Stemmer · 2003 [cited by applicant]
US 6506603B1 · Stemmer · 2003 [cited by applicant]
US 6518065B1 · Stemmer · 2003 [cited by applicant]
US 6519065B1 · Colbourne et al. · 2003 [cited by applicant]
US 6521453B1 · Crameri et al. · 2003 [cited by applicant]
US 6528311B1 · delCardayre et al. · 2003 [cited by applicant]
US 6537746B2 · Arnold et al. · 2003 [cited by applicant]
US 6573098B1 · Stemmer · 2003 [cited by applicant]
US 6576467B1 · Stemmer · 2003 [cited by applicant]
US 6579678B1 · Patten et al. · 2003 [cited by applicant]
US 6586182B1 · Patten et al. · 2003 [cited by applicant]
US 6602986B1 · Stemmer et al. · 2003 [cited by applicant]
US 6605430B1 · Affholter et al. · 2003 [cited by applicant]
US 6613514B2 · Patten et al. · 2003 [cited by applicant]
US 6653072B1 · Patten et al. · 2003 [cited by applicant]
US 6686515B1 · Lassner et al. · 2004 [cited by applicant]
US 6703240B1 · Stemmer et al. · 2004 [cited by applicant]
US 6716631B1 · delCardayre et al. · 2004 [cited by applicant]
US 6825001B2 · Wackett et al. · 2004 [cited by applicant]
US 6902922B2 · Ness et al. · 2005 [cited by applicant]
US 6917882B2 · Selifonov et al. · 2005 [cited by applicant]
US 6946296B2 · Patten et al. · 2005 [cited by applicant]
US 6961664B2 · Selifonov et al. · 2005 [cited by applicant]
US 6995017B1 · Stemmer · 2006 [cited by applicant]
US 7024312B1 · Selifonov et al. · 2006 [cited by applicant]
US 7058515B1 · Selifonov et al. · 2006 [cited by applicant]
US 7105297B2 · Minshull et al. · 2006 [cited by applicant]
US 7148054B2 · delCardayre et al. · 2006 [cited by applicant]
US 7220566B2 · Ness et al. · 2007 [cited by applicant]
US 7288375B2 · Stemmer et al. · 2007 [cited by applicant]
US 7384387B1 · Raillard et al. · 2008 [cited by applicant]
US 7421347B2 · Selifonov et al. · 2008 [cited by applicant]
US 7430477B2 · Selifonov et al. · 2008 [cited by applicant]
US 7462469B2 · Raillard et al. · 2008 [cited by applicant]
US 7534564B2 · Patten et al. · 2009 [cited by applicant]
US 7620500B2 · Mundorff et al. · 2009 [cited by applicant]
US 7620502B2 · Selifonov et al. · 2009 [cited by applicant]
US 7629170B2 · delCardayre et al. · 2009 [cited by applicant]
US 7702464B1 · Emig et al. · 2010 [cited by applicant]
US 7747391B2 · Gustafsson et al. · 2010 [cited by applicant]
US 7747393B2 · Fox · 2010 [cited by applicant]
US 7751986B2 · Gustafsson et al. · 2010 [cited by applicant]
US 7776598B2 · Patten et al. · 2010 [cited by applicant]
US 7783428B2 · Gustafsson et al. · 2010 [cited by applicant]
US 7795030B2 · Minshull et al. · 2010 [cited by applicant]
US 7853410B2 · Selifonov et al. · 2010 [cited by applicant]
US 7868138B2 · Stemmer et al. · 2011 [cited by applicant]
US 7873477B1 · Gustafsson et al. · 2011 [cited by applicant]
US 7873499B2 · Selifonov et al. · 2011 [cited by applicant]
US 7904249B2 · Selifonov et al. · 2011 [cited by applicant]
US 7957912B2 · Selifonov et al. · 2011 [cited by applicant]
US 7981614B2 · Stemmer et al. · 2011 [cited by applicant]
US 8014961B2 · Bass et al. · 2011 [cited by applicant]
US 8029988B2 · Crameri et al. · 2011 [cited by applicant]
US 8048674B2 · Minshull et al. · 2011 [cited by applicant]
US 8058001B2 · Minshull et al. · 2011 [cited by applicant]
US 8076138B2 · delCardayre et al. · 2011 [cited by applicant]
US 8108150B2 · Mundorff et al. · 2012 [cited by applicant]
US 8170806B2 · Selifonov et al. · 2012 [cited by applicant]
US 8224580B2 · Mundorff et al. · 2012 [cited by applicant]
US 8377681B2 · delCardayre et al. · 2013 [cited by applicant]
US 8383346B2 · Colbeck et al. · 2013 [cited by applicant]
US 8457903B1 · Emig et al. · 2013 [cited by applicant]
US 8504498B2 · Fox · 2013 [cited by applicant]
US 8589085B2 · Selifonov et al. · 2013 [cited by applicant]
US 8762066B2 · Fox · 2014 [cited by applicant]
US 8768871B2 · Fox · 2014 [cited by applicant]
US 9593326B2 · Clark et al. · 2017 [cited by applicant]
US 9665694B2 · Cope · 2017 [cited by applicant]
US 9684771B2 · Cope et al. · 2017 [cited by applicant]
US 9714437B2 · Chan et al. · 2017 [cited by applicant]
US 20080220990A1 · Fox · 2008 [cited by applicant]
US 20090312196A1 · Colbeck et al. · 2009 [cited by applicant]
WO 9522625A1 · 1995 [cited by applicant]
WO 9533836A1 · 1995 [cited by applicant]
WO 9600787A1 · 1996 [cited by applicant]
WO 970078A1 · 1997 [cited by applicant]
WO 9735966A1 · 1997 [cited by applicant]
WO 9827230A1 · 1998 [cited by applicant]
WO 200042651A1 · 2000 [cited by applicant]
WO 200175767A2 · 2001 [cited by applicant]
WO 2009008908A2 · 2009 [cited by applicant]
WO 2009091228A2 · 2009 [cited by applicant]
WO 2009152336A1 · 2009 [cited by applicant]
Garenne, D., Haines, M.C., Romantseva, E.F. et al. Cell-free gene expression. Nat Rev Methods Primers 1, 49 (2021). https://doi.org/10.1038/s43586-021-00046-x (Year: 2021). [cited by examiner]
Putnam et al. (The amphioxus genome and the evolution of the chordate karyotype. Nature 453:1064-1071(2008) (Year: 2008). [cited by examiner]
Smith, M., “In vitro mutagenesis,” Ann. Rev. Genet., 19:423-462 (1985). [cited by applicant]
Smith, T., et al., “Comparison of Biosequences,” Adv. Appl. Math, 2:482-489 (1981). [cited by applicant]
Stehle, T., et al., “Refined structure of the complex between guanylate kinase and its substrate GMP at 2.0 A resolution.” Journal of molecular biology, 224(4):1127-41 (1992). [cited by applicant]
Stemmer, W., “DNA Shuffling by Random Fragmentation and Reassembly: In vitro Recombination for Molecular Evolution,” Proc. Natl. Acad. Sci. USA, 91:10747-10751 (1994). [cited by applicant]
Stemmer, W.P.C., “Rapid evolution of a protein in vitro by DNA shuffling”, Nature, 370:389-391 (1994). [cited by applicant]
Stenico, M., et al., “Codon usage in Caenorhabditis elegans: delineation of translational selection and mutational biases,” Nucl. Acids Res. 22(13):2437-46 [1994]. [cited by applicant]
Suggs, S.V., et al., “Use of synthetic oligodeoxyribonucleotides for the isolation of specific cloned DNA sequenes,” In Developmental Biology Using Purified Genes (Brown et al., eds.), pp. 683-693, Academic Press (1981). [cited by applicant]
Takahashi, T., et al., “Efficient gene disruption in the koji-mold Aspergillus sojae using a novel variation of the positive-negative method,” Mol. Gen. Genom., 272: 344-352 [2004]. [cited by applicant]
Tiwari, S., et al., “Prediction of probable genes by Fourier analysis of genomic sequences,” Comput. Appl. Biosci. 13 (3):263-270 [1997]. [cited by applicant]
Truppo, M.D., et al., “Development of an Improved Immobilized CAL-B for the Enzymatic Resolution of a Key Intermediate to Odanacatib,” Organic Process Research & Development, 15:1033-1035 (2011). [cited by applicant]
Uberbacher, E.C., et al., “Discovering and Understanding Genes in Human DNA Sequence Using GRAIL,” Methods Enzymol., 266:259-281 [1996]. [cited by applicant]
Villa-Komaroff, L., et al., “A bacterial clone synthesizing proinsulin,” Proc. Natl Acad. Sci. USA, 75:3727-3731 (1978). [cited by applicant]
Wada, K., et al., “Codon usage tabulated from the GenBank genetic sequence data,” Nucl. Acids Res., 20:2111-2118 [1992]. [cited by applicant]
Wells, J.A., et al., “Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites,” Gene, 34:315-323 (1985). [cited by applicant]
Wetmur, J. G., “DNA Probes: Applications of the Principles of Nucleic Acid Hybridization,” Crit Rev Biochem Mol Biol, 26(3/4):227-259 (1991). [cited by applicant]
Wilson, I.A., et al., “The structure of antigenic determinant in a protein,” Cell, 37:767-778 [1984]. [cited by applicant]
Wright, F., “The ‘effective number of codons’ used in a gene,” Gene 87:23-29 [1990]. [cited by applicant]
Yi, S., et al., “Covalent immobilization of omega-transaminase from Vibrio fluvialis JS17 on chitosan beads,” Process Biochemistry 42(5): 895-898 (2007). [cited by applicant]
You, B., et al., “Gene-specifc disruption in the fillamentous fungus Cercospora nicotianae using a split-marker approach,” Arch Microbiol., 191:615-622 [2009]. [cited by applicant]
Zhang, J-H., et al., “Directed evolution of a fucosidase from a galactosidase by DNA shuffling and screening ,”Proc. Nat. Acad. Sci., U.S.A., 94:4504-4509 (1997). [cited by applicant]
UniProt Accession No. C3YEM4 dated Jul. 28, 2009. [cited by applicant]
Altschul, S., et al., “Basic local alignment search tool,” J. Mol. Biol., 215: 403-410 (1990). [cited by applicant]
Altschul, S.F., et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Res., 25(17):3389-3402 (1997). [cited by applicant]
Baldino, Jr., F., et al., “High-Resolution in Situ Hybridization Histochemistry,” Methods Enzymology, 168:761-777 (1989). [cited by applicant]
Batzer, M.A., “Erratum: Structure and variability of recently inserted Alu family members”, Nucleic Acids Res 19:698-699 [1991]. [cited by applicant]
Bolton, E.T., et al., “A General Method for the lisolation of RNA Complementary to DNA,” Proc. Natl. Acad. Sci. USA 48:1390 ( 1962). [cited by applicant]
Botstein, D., et al., “Strategies and applications of in vitro mutagenesis,” Science, 229(4719):1193-1201 [1985]. [cited by applicant]
Breslauer, K.J., et al., “Predicting DNA duplex stability from the base sequence,” Proc. Natl. Acad. Sci. USA, 83:3746-3750 (1986). [cited by applicant]
Carter, P., “Site-directed mutagenesis,” Biochem. J., 237:1-7 (1986). [cited by applicant]
Chaveroche, M., et al., “A rapid method for efficient gene replacement in the filamentous fungus Aspergillus nidulans,” Nucl. Acids Res., 28:22 e97 [2000]. [cited by applicant]
Cho, Y., et al., “A high throughput targeted gene disruption method for Alternaria brassicicola functional genomics using linear minimal element (LME) constructs,” Mol Plant Microbe Interact, 19(1):7-15 [2006]. [cited by applicant]
Christians, F.C., et al., “Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling,” Nat. Biotechnol., 17:259-264 (1999). [cited by applicant]
Combier, J.-P., et al., “Agrobacterium tumefaciens-mediated transformation as a tool for insertional mutagenesis in the symbiotic ectomycorrhizal fungus Hebeloma cylindrosporum,” FEMS Microbiol Lett., 220:141-8 [2003]. [cited by applicant]
Crameri, A., et al., “DNA shuffling of a family of genes from diverse species accelerates directed evolution”, Nature, 391:288-291 (1998). [cited by applicant]
Crameri, A., et al., “Improved green fluorescent protein by molecular evolution using DNA shuffling,” Nat. Biotechnol., 14(3):315-319 (1996). [cited by applicant]
Crameri, A., et al., “Molecular evolution of an arsenate detoxification pathway by DNA shuffling,” Nat. Biotechnol., 15 (5):436-438 (1997). [cited by applicant]
Dale, S.J., et al., “Oligonucleotide-directed random mutagenesis using the phosphorothioate method,” Methods Mol. Biol., 57:369-74 (1996). [cited by applicant]
De Boer, H.A., et al., “The tac promoter: A functional hybrid derived from the trp and lac promoters,” Proc. Natl Acad. Sci. USA, 80: 21-25 (1983). [cited by applicant]
Ehrlich, S.D., “DNA cloning in [cited by applicant]
Eisenberg, D., et al., “Analysis of Membrane and Surface Protein Sequences with the Hydrophobic Moment Plot,” J. Mol. Biol., 179:125-142 [1984]. [cited by applicant]
Fasman, G.D.,CRC Practical Handbook of Biochemistry and Molecular Biology, CRC Press, Boca Raton, FL, pp. 3-70 [1989]. [cited by applicant]
Firon, A., et al., “Identification of Essential Genes in the Human Fungal Pathogen Aspergillus fumigatus by Transposon Mutagenesis,” Eukaryot. Cell, 2(2):247-55 [2003]. [cited by applicant]
Freier, S.M., et al., “Improved free-energy parameters for predictions of RNA duplex stability,” Proc. Natl. Acad. Sci USA, 83:9373-9377 (1986). [cited by applicant]
Gao, P., et al., “Cyclic [G(2′,5′)pA(3′,5′)p] Is the Metazoan Second Messenger Produced by DNA-Activated Cyclic GMP-AMP Synthase,” Cell. 153(5): 1094-1107 [2013]. [cited by applicant]
Guo, Z., et al., “3′-End-Forming Signals of Yeast mRNA,” Mol. Cell. Biol., 15(11):5983-5990 [1995]. [cited by applicant]
Henaut and Danchin in Neidhardt et al. [eds.], [cited by applicant]
Henikoff, S.,et al., “Amino acid substitution matrices from protein blocks,” Proc. Natl. Acad. Sci., 89:10915-10919 (1992). [cited by applicant]
Hong, J., et al., “Cloning and functional expression of thermostable beta-glucosidase gene from Thermoascus aurantiacus,” Appl. Microbiol. Biotechnol, 73:1331-1339 [2007]. [cited by applicant]
Kandeel, M. et al., “Molecular cloning, expression, characterization and mutation of Plasmodium falciparum guanylate kinase”, Molecular and Biochemical Parasitology, 159(2):130-133 [2008]. [cited by applicant]
Kierzek, R., et al., “Polymer-Supported RNA Synthesis and Its Application To Test the Nearest-Neighbor Model for Duplex Stability,” Biochemistry, 25:7840-7846 (1986). [cited by applicant]
Koszelewski, D., et al., “Immobilization of omega-transaminases by encapsulation in a sol-gel/celite matrix,” Journal of Molecular Catalysis B: Enzymatic, 63: 39-44 (2010). [cited by applicant]
Kramer, B., et al., “Different base/base mismatches are corrected with different efficiencies by the methyl-directed DNA mismatch-repair system of [cited by applicant]
Kranzusch, P.J., et al., “Structure of Human Cgas Reveals a Conserved Family of Second-Messenger Enzymes in Innate Immunity,” Cell Rep., 3(5): 1362-1368 [2013]. [cited by applicant]
Lathe, R., et al., “Plasmid and bacteriophage vectors for excision of intact inserts,” Gene, 57:193-201 (1987). [cited by applicant]
Li, T., et al., “Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMPSTING-IRF3 Mediated Innate Immune Response,” Sci. Rep., 6:19049 [2016]. [cited by applicant]
Ling, M., et al., “Approaches to DNA Mutagenesis:An Overview,” Anal. Biochem., 254:157-78 (1997). [cited by applicant]
Martin, A.R., et al., “Characterization of free and immobilized (S)-aminotransferase for acetophenone production,” Applied Microbiology and Biotechnology, 76(4): 843-851 (2007). [cited by applicant]
Maruyama, J., “Multiple gene disruptions by marker recycling with highly efficient gene-targeting background (delta-ligD) in Aspergillus oryzae,” Biotechnol Lett., 30:1811-1817 [2008]. [cited by applicant]
Mateo, C., et al., “Epoxy sepabeads: a novel epoxy support for stabilization of industrial enzymes via very intense multipoint covalent attachment,” Biotechnology Progress 18(3):629-34 (2002). [cited by applicant]
Mcinerney, J.O., “GCUA: general codon usage analysis,” Bioinformatics, 14(4):372-73, 1998. [cited by applicant]
Mcintosh, J.A., et al., “A kinase-cGAS cascade to synthesize a therapeutic STING activator”, Nature, 603(7901):439-444, [2022]. [cited by applicant]
Mertlkov-Kaiserov, H., et al., “Point mutations in human guanylate kinase account for acquired resistance to anticancer nucleotide analogue PMEG”, Biochemical Pharmacology, 82(2):131-138, [2011]. [cited by applicant]
Minshull, J., et al., “Protein evolution by molecular breeding,” Curr. Op. Chem. Biol., 3(3):284-290 (1999). [cited by applicant]
Nakamura, Y., et al., “Codon usage tabulated from international DNA sequence databases: status for the year 2000,” Nucl. Acids Res., 28:292 [2000]. [cited by applicant]
Needleman, S., et al., “A general method applicable to the search for similarities in the amino acid sequence of two proteins,” J. Mol. Biol. 48:443-453 (1970). [cited by applicant]
Parry, N.J., et al., “Biochemical characterization and mechanism of action of a thermostablebeta-glucosidase purified from Thermoascus aurantiacus,” Biochem. J., 353:117-127 [2001]. [cited by applicant]
Pearson, W.R., “Improved tools for biological sequence comparison,” Proc. Nat'l. Acad. Sci. USA, 85:2444-2448 (1988). [cited by applicant]
Porath, J., “Immobilized metal ion affinity chromatography,” Protein Expression and Purification, 3:263-281 (1992). [cited by applicant]
Romanos, M.A., et al., “Foreign gene expression in yeast: a review,” Yeast 8:423-488 [1992]. [cited by applicant]
Rychlik, W., et al., “Optimization of the annealing temperature for DNA amplification in vitro,” Nucleic Acids Res, 18 (21):6409-6412 (1990). [cited by applicant]
Simonen, M., et al., “Protein Secretion in Bacillus Species,” Microbiological Reviews, 57:109-137 (1993). [cited by applicant]